CD8A and neoplasm: Tumor-infiltrating CD8+ T cells showed a synergistic enhancement against an immunizing peptide in the Vax/aGITR/aPD-1 combination therapy, indicating that the superior induction of potent CTL responses was most likely critical for the efficacy of the combination therapy.